Biography and Research Information
OverviewAI-generated summary
Lauren Gawey's research focuses on postmarketing safety surveillance of medications used to treat hidradenitis suppurativa and atopic dermatitis. Gawey analyzes data from the Food and Drug Administration Adverse Events Reporting System (FAERS) to investigate real-world adverse events linked to specific drugs, including adalimumab, secukinumab, infliximab, and upadacitinib. This work also includes examining boxed warning-related adverse events and the readability of AI-generated health information. Additionally, Gawey has studied national funding trends in dermatology. Gawey collaborates with researchers from the University of Arkansas for Medical Sciences, including Khiem A. Tran, Carissa Saadi, Jay Kincannon, and Hannah Wu, with whom Gawey has multiple shared publications. Gawey's scholarly output includes 20 publications and has an h-index of 3.
Metrics
- h-index: 3
- Publications: 20
- Citations: 21
Selected Publications
-
Lifestyle Modifications and Nonpharmacological Treatments in Hidradenitis Suppurativa (2025)
-
Analysis of Ingredients, Safety Hazards, and Marketing Claims of Popular Insect Repellents (2024)
-
50972 Allergens and Marketing Claims of Popular Over-the Counter Acne Washes (2024)
-
53391 ChatGPT as a Hidradenitis Suppurativa Resource: A Comparison of Internet Resource Readability (2024)
-
53436 Treatment Adherence in Hidradenitis Suppurativa: A Systematic Review (2024)
-
53413 The Buzz Behind Insect Repellents: Analysis of Safety Hazards, Marketing Claims, and Ingredients (2024)
-
Readability of Information Generated by ChatGPT for Hidradenitis Suppurativa (2024)
-
Allergenicity and marketing characteristics of 100 popular over-the-counter acne treatments (2024)
Collaboration Network
Top Collaborators
- Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database
- Postmarketing safety analysis of upadacitinib in atopic dermatitis: A Food and Drug Administration adverse reporting system review of boxed warning-related adverse events
- Readability of Information Generated by ChatGPT for Hidradenitis Suppurativa
- Lifestyle Modifications and Nonpharmacological Treatments in Hidradenitis Suppurativa
- National Institutes of Health Dermatology Funding Trends: 2020–2024
Showing 5 of 19 shared publications
- Postmarketing safety analysis of upadacitinib in atopic dermatitis: A Food and Drug Administration adverse reporting system review of boxed warning-related adverse events
- Readability of Information Generated by ChatGPT for Hidradenitis Suppurativa
- Lifestyle Modifications and Nonpharmacological Treatments in Hidradenitis Suppurativa
- National Institutes of Health Dermatology Funding Trends: 2020–2024
- Readability of Information Generated by ChatGPT for Hidradenitis Suppurativa (Preprint)
Showing 5 of 18 shared publications
- Readability of Information Generated by ChatGPT for Hidradenitis Suppurativa
- Lifestyle Modifications and Nonpharmacological Treatments in Hidradenitis Suppurativa
- Readability of Information Generated by ChatGPT for Hidradenitis Suppurativa (Preprint)
- Allergenicity and marketing characteristics of 100 popular over-the-counter acne treatments
- 53413 The Buzz Behind Insect Repellents: Analysis of Safety Hazards, Marketing Claims, and Ingredients
Showing 5 of 13 shared publications
- Postmarketing safety analysis of upadacitinib in atopic dermatitis: A Food and Drug Administration adverse reporting system review of boxed warning-related adverse events
- Readability of Information Generated by ChatGPT for Hidradenitis Suppurativa
- Readability of Information Generated by ChatGPT for Hidradenitis Suppurativa (Preprint)
- Allergenicity and marketing characteristics of 100 popular over-the-counter acne treatments
- 53413 The Buzz Behind Insect Repellents: Analysis of Safety Hazards, Marketing Claims, and Ingredients
Showing 5 of 12 shared publications
- Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database
- Postmarketing safety analysis of upadacitinib in atopic dermatitis: A Food and Drug Administration adverse reporting system review of boxed warning-related adverse events
- National Institutes of Health Dermatology Funding Trends: 2020–2024
- Bibliometric Analysis in Hyperhidrosis: Recent Publication Trends from 2015 to 2025
- Hyperhidrosis Clinical Trial Disparities: Enrollment and Reporting Trends
Showing 5 of 9 shared publications
- Readability of Information Generated by ChatGPT for Hidradenitis Suppurativa
- Readability of Information Generated by ChatGPT for Hidradenitis Suppurativa (Preprint)
- Allergenicity and marketing characteristics of 100 popular over-the-counter acne treatments
- 53391 ChatGPT as a Hidradenitis Suppurativa Resource: A Comparison of Internet Resource Readability
- Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database
- 64893 Adalimumab and Hidradenitis Suppurativa: An Review of Post-Marketing Adverse Events Data From the FDA Adverse Event Reporting System
- 64837 Pharmacovigilance Insights into Secukinumab Safety in Hidradenitis Suppurativa from the FDA Adverse Event Reporting System (FAERS)
- 64874 Real-World Adverse Events Linked to Infliximab in Hidradenitis Suppurativa: A FAERS Investigation
- 53413 The Buzz Behind Insect Repellents: Analysis of Safety Hazards, Marketing Claims, and Ingredients
- 53436 Treatment Adherence in Hidradenitis Suppurativa: A Systematic Review
- Analysis of Ingredients, Safety Hazards, and Marketing Claims of Popular Insect Repellents
- Postmarketing safety analysis of upadacitinib in atopic dermatitis: A Food and Drug Administration adverse reporting system review of boxed warning-related adverse events
- National Institutes of Health Dermatology Funding Trends: 2020–2024
- Bibliometric Analysis in Hyperhidrosis: Recent Publication Trends from 2015 to 2025
- 53413 The Buzz Behind Insect Repellents: Analysis of Safety Hazards, Marketing Claims, and Ingredients
- Analysis of Ingredients, Safety Hazards, and Marketing Claims of Popular Insect Repellents
- Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database
- Analysis of Ingredients, Safety Hazards, and Marketing Claims of Popular Insect Repellents
- National Institutes of Health Dermatology Funding Trends: 2020–2024
- Hyperhidrosis Clinical Trial Disparities: Enrollment and Reporting Trends
- National Institutes of Health Dermatology Funding Trends: 2020–2024
- Bibliometric Analysis in Hyperhidrosis: Recent Publication Trends from 2015 to 2025
- Allergenicity and marketing characteristics of 100 popular over-the-counter acne treatments
- Allergenicity and marketing characteristics of 100 popular over-the-counter acne treatments
Similar Researchers
Based on overlapping research topics